{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:34:26Z","timestamp":1792092866668,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with a heterogeneous clinical behavior. In 5\u201310% of patients the disease transforms into a diffuse large-B cell lymphoma known as Richter transformation (RT), which is associated with dismal prognosis. Here, we aimed to establish patient-derived xenograft (PDX) models to study the molecular features and evolution of CLL and RT. We generated two PDXs by injecting CLL (PDX12) and RT (PDX19) cells into immunocompromised NSG mice. Both PDXs were morphologically and phenotypically similar to RT. Whole-genome sequencing analysis at different time points of the PDX evolution revealed a genomic landscape similar to RT tumors from both patients and uncovered an unprecedented RT subclonal heterogeneity and clonal evolution during PDX generation. In PDX12, the transformed cells expanded from a very small subclone already present at the CLL stage. Transcriptomic analysis of PDXs showed a high oxidative phosphorylation (OXPHOS) and low B-cell receptor (BCR) signaling similar to the RT in the patients. IACS-010759, an OXPHOS inhibitor, reduced proliferation, and circumvented resistance to venetoclax. In summary, we have generated new RT-PDX models, one of them from CLL cells that mimicked the evolution of CLL to RT uncovering intrinsic features of RT cells of therapeutical value.<\/jats:p>","DOI":"10.1038\/s41375-023-02095-5","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T11:02:58Z","timestamp":1701169378000},"page":"557-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3447-3848","authenticated-orcid":false,"given":"Heribert","family":"Playa-Albinyana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Royo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Gir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6756-1820","authenticated-orcid":false,"given":"Irene","family":"L\u00f3pez-Oreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Aymerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f2nica","family":"L\u00f3pez-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6794-6456","authenticated-orcid":false,"given":"Gerard","family":"Frigola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Be\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5157-4376","authenticated-orcid":false,"given":"Julio","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo M.","family":"Garcia-Roves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-9793","authenticated-orcid":false,"given":"El\u00edas","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-9440","authenticated-orcid":false,"given":"Ferran","family":"Nadeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7486-8484","authenticated-orcid":false,"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"2095_CR1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pathmechdis-012419-032810","volume":"15","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Diaz-Navarro A, Delgado J, Puente XS, Campo E. Genomic and epigenomic alterations in chronic lymphocytic leukemia. Annu Rev Pathol: Mech Dis. 2020;15:149\u201377.","journal-title":"Annu Rev Pathol: Mech Dis"},{"key":"2095_CR2","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","volume":"105","author":"J Delgado","year":"2020","unstructured":"Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica 2020;105:2205\u201317.","journal-title":"Haematologica"},{"key":"2095_CR3","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ng.2443","volume":"44","author":"M Kulis","year":"2012","unstructured":"Kulis M, Heath S, Bibikova M, Queir\u00f3s AC, Navarro A, Clot G, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44:1236\u201342.","journal-title":"Nat Genet"},{"key":"2095_CR4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente XS, Be\u00e0 S, Vald\u00e9s-Mas R, Villamor N, Guti\u00e9rrez-Abril J, Mart\u00edn-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015;526:519\u201324.","journal-title":"Nature"},{"key":"2095_CR5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015;526:525\u201330.","journal-title":"Nature"},{"key":"2095_CR6","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","volume":"54","author":"BA Knisbacher","year":"2022","unstructured":"Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022;54:1664\u201374.","journal-title":"Nat Genet"},{"key":"2095_CR7","doi-asserted-by":"crossref","first-page":"829983","DOI":"10.3389\/fonc.2022.829983","volume":"12","author":"A Condoluci","year":"2022","unstructured":"Condoluci A, Rossi D. Biology and treatment of Richter transformation. Front Oncol. 2022;12:829983.","journal-title":"Front Oncol"},{"key":"2095_CR8","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","volume":"131","author":"D Rossi","year":"2018","unstructured":"Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood 2018;131:2761\u201372.","journal-title":"Blood"},{"key":"2095_CR9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.22.01028","volume":"41","author":"E Smyth","year":"2023","unstructured":"Smyth E, Eyre TA, Cheah CY. Emerging therapies for the management of Richter transformation. J Clin Oncol. 2023;41:395\u2013409.","journal-title":"J Clin Oncol"},{"key":"2095_CR10","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","volume":"137","author":"J Klintman","year":"2021","unstructured":"Klintman J, Appleby N, Stamatopoulos B, Ridout K, Eyre TA, Robbe P, et al. Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. Blood 2021;137:2800\u201316.","journal-title":"Blood"},{"key":"2095_CR11","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","volume":"28","author":"F Nadeu","year":"2022","unstructured":"Nadeu F, Royo R, Massoni-Badosa R, Playa-Albinyana H, Garcia-Torre B, Duran-Ferrer M, et al. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. Nat Med. 2022;28:1662\u201371.","journal-title":"Nat Med"},{"key":"2095_CR12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","volume":"29","author":"EM Parry","year":"2023","unstructured":"Parry EM, Leshchiner I, Gui\u00e8ze R, Johnson C, Tausch E, Parikh SA, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023;29:158\u201369.","journal-title":"Nat Med"},{"key":"2095_CR13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/17460441.2021.1935860","volume":"16","author":"H Playa-Albinyana","year":"2021","unstructured":"Playa-Albinyana H, Arenas F, Colomer D. Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery. Expert Opin Drug Discov. 2021;16:1085\u201390.","journal-title":"Expert Opin Drug Discov"},{"key":"2095_CR14","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","volume":"99","author":"R Bichi","year":"2002","unstructured":"Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA. 2002;99:6955\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2095_CR15","doi-asserted-by":"crossref","first-page":"11713","DOI":"10.1073\/pnas.0604564103","volume":"103","author":"X Yan","year":"2006","unstructured":"Yan X, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci. 2006;103:11713\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"2095_CR16","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41375-018-0260-4","volume":"33","author":"N Zaborsky","year":"2019","unstructured":"Zaborsky N, Gassner FJ, H\u00f6pner JP, Schubert M, Hebenstreit D, Stark R, et al. Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. Leukemia 2019;33:957\u201368.","journal-title":"Leukemia"},{"key":"2095_CR17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ccell.2016.10.005","volume":"30","author":"L Wang","year":"2016","unstructured":"Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, et al. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. Cancer Cell. 2016;30:750\u201363.","journal-title":"Cancer Cell"},{"key":"2095_CR18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","volume":"13","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13:4.","journal-title":"J Hematol Oncol"},{"key":"2095_CR19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","volume":"19","author":"ER Zanella","year":"2022","unstructured":"Zanella ER, Grassi E, Trusolino L. Towards precision oncology with patient-derived xenografts. Nat Rev Clin Oncol. 2022;19:719\u201332.","journal-title":"Nat Rev Clin Oncol"},{"key":"2095_CR20","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-17-4004","volume":"78","author":"T Vaisitti","year":"2018","unstructured":"Vaisitti T, Braggio E, Allan JN, Arruga F, Serra S, Zam\u00f2 A, et al. Novel Richter Syndrome Xenograft Models to study genetic architecture, biology, and therapy responses. Cancer Res. 2018;78:3413\u201320.","journal-title":"Cancer Res"},{"key":"2095_CR21","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41375-021-01181-w","volume":"35","author":"W Fiskus","year":"2021","unstructured":"Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, et al. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia 2021;35:2621\u201334.","journal-title":"Leukemia"},{"key":"2095_CR22","doi-asserted-by":"crossref","unstructured":"ten Hacken E, Yin S, Redd RA, Hern\u00e1ndez S\u00e1nchez M, Clement K, Brunsting Hoffmann G, et al. Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models. Blood Adv. 2023;7:4514-7.","DOI":"10.1182\/bloodadvances.2022009135"},{"key":"2095_CR23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model. Comput Struct Biotechnol J 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"2095_CR24","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488\u201393.","journal-title":"Nucleic Acids Res"},{"key":"2095_CR25","doi-asserted-by":"crossref","first-page":"e202301955","DOI":"10.26508\/lsa.202301955","volume":"6","author":"I L\u00f3pez-Oreja","year":"2023","unstructured":"L\u00f3pez-Oreja I, Gohr A, Playa-Albinyana H, Gir\u00f3 A, Arenas F, Higashi M, et al. SF3B1 mutation\u2013mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia. Life Sci Alliance. 2023;6:e202301955.","journal-title":"Life Sci Alliance"},{"key":"2095_CR26","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood.2020008311","volume":"137","author":"F Nadeu","year":"2021","unstructured":"Nadeu F, Royo R, Clot G, Duran-Ferrer M, Navarro A, Mart\u00edn S, et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood 2021;137:2935\u201346.","journal-title":"Blood"},{"key":"2095_CR27","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1073\/pnas.1913810117","volume":"117","author":"PC Maity","year":"2020","unstructured":"Maity PC, Bilal M, Koning MT, Young M, van Bergen CAM, Renna V, et al. IGLV3-21 * 01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proc Natl Acad Sci. 2020;117:4320\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"2095_CR28","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24:1036\u201346.","journal-title":"Nat Med"},{"key":"2095_CR29","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:716\u201335.","journal-title":"Cancer Discov"},{"key":"2095_CR30","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","volume":"2","author":"C Bosc","year":"2021","unstructured":"Bosc C, Saland E, Bousard A, Gadaud N, Sabatier M, Cognet G, et al. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nat Cancer. 2021;2:1204\u201323.","journal-title":"Nat Cancer"},{"key":"2095_CR31","unstructured":"Chen Z, Cretenet G, Carnazzo V, Simon-Molas H, Kater AP, van der Windt GJW, et al. Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia. Haematologica. (in press)."},{"key":"2095_CR32","doi-asserted-by":"crossref","first-page":"627020","DOI":"10.3389\/fimmu.2021.627020","volume":"12","author":"PEM Patten","year":"2021","unstructured":"Patten PEM, Ferrer G, Chen SS, Kolitz JE, Rai KR, Allen SL, et al. A detailed analysis of parameters supporting the engraftment and growth of chronic lymphocytic leukemia cells in immune-deficient mice. Front Immunol. 2021;12:627020.","journal-title":"Front Immunol"},{"key":"2095_CR33","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2021011993","volume":"138","author":"E ten Hacken","year":"2021","unstructured":"ten Hacken E, Wu CJ. Understanding CLL biology through mouse models of human genetics. Blood 2021;138:2621\u201331.","journal-title":"Blood"},{"key":"2095_CR34","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","volume":"137","author":"T Vaisitti","year":"2021","unstructured":"Vaisitti T, Arruga F, Vitale N, Lee T-T, Ko M, Chadburn A, et al. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient\u2013derived xenograft mouse models. Blood 2021;137:3365\u201377.","journal-title":"Blood"},{"key":"2095_CR35","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3324\/haematol.2017.173419","volume":"102","author":"T Vaisitti","year":"2017","unstructured":"Vaisitti T, Gaudino F, Ouk S, Moscvin M, Vitale N, Serra S, et al. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-\u03baB inhibitor. Haematologica 2017;102:1878\u201389.","journal-title":"Haematologica"},{"key":"2095_CR36","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.2020010187","volume":"137","author":"A Iannello","year":"2021","unstructured":"Iannello A, Vitale N, Coma S, Arruga F, Chadburn A, Di Napoli A, et al. Synergistic efficacy of the dual PI3K-\u03b4\/\u03b3 inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood 2021;137:3378\u201389.","journal-title":"Blood"},{"key":"2095_CR37","doi-asserted-by":"crossref","unstructured":"Chen S-S. Method for generating a patient-derived Xenograft Model of CLL. Methods Mol Biol. 2019;1881:165-71.","DOI":"10.1007\/978-1-4939-8876-1_13"},{"key":"2095_CR38","doi-asserted-by":"publisher","unstructured":"Liu H, Miao Y, Ferrajoli A, Tang G, McDonnell T, Medeiros LJ, et al. Leukemic phase of Richter transformation: A mimic of acute myeloid leukemia that responded to Ibrutinib monotherapy. Am J Hematol. 2020. https:\/\/doi.org\/10.1002\/ajh.25782.","DOI":"10.1002\/ajh.25782"},{"key":"2095_CR39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/bloodadvances.2021006941","volume":"7","author":"C Sun","year":"2023","unstructured":"Sun C, Chen YC, Martinez Zurita A, Baptista MJ, Pittaluga S, Liu D, et al. The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia. Blood Adv. 2023;7:145\u201358.","journal-title":"Blood Adv"},{"key":"2095_CR40","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Sinha S, Wellik LE, Secreto CR, Rech KL, Call TG, et al. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer J. 2021;11:86.","journal-title":"Blood Cancer J"},{"key":"2095_CR41","doi-asserted-by":"crossref","unstructured":"ten Hacken E, Sewastianik T, Yin S, Brunsting Hoffmann G, Gruber M, Clement K, et al. In vivo modeling of CLL transformation to Richter\u2019s syndrome reveals convergent evolutionary paths and therapeutic vulnerabilities. Blood Cancer Discov. 2023;4:150-69.","DOI":"10.1158\/2643-3230.BCD-22-0082"},{"key":"2095_CR42","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s43018-021-00216-6","volume":"2","author":"J Lu","year":"2021","unstructured":"Lu J, Cannizzaro E, Meier-Abt F, Scheinost S, Bruch PM, Giles HAR, et al. Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. Nat Cancer. 2021;2:853\u201364.","journal-title":"Nat Cancer"},{"key":"2095_CR43","doi-asserted-by":"crossref","unstructured":"Parry EM, ten Hacken E, Wu CJ. Richter syndrome: Novel insights into the biology of transformation. Blood. 2023;142:11-22.","DOI":"10.1182\/blood.2022016502"},{"key":"2095_CR44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32368-z","volume":"13","author":"J Edwards-Hicks","year":"2022","unstructured":"Edwards-Hicks J, Su H, Mangolini M, Yoneten KK, Wills J, Rodriguez-Blanco G, et al. MYC sensitises cells to apoptosis by driving energetic demand. Nat Commun. 2022;13:4674.","journal-title":"Nat Commun"},{"key":"2095_CR45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/cancers15010062","volume":"15","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Mei Y, Wang Z, He W. The effect of oxidative phosphorylation on cancer drug resistance. Cancers. 2022;15:62.","journal-title":"Cancers"},{"key":"2095_CR46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","volume":"129","author":"JH Myklebust","year":"2017","unstructured":"Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, W\u00e4lchli S, et al. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood 2017;129:759\u201370.","journal-title":"Blood"},{"key":"2095_CR47","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bjh.14062","volume":"177","author":"K-L Chan","year":"2017","unstructured":"Chan K-L, Blombery P, Jones K, Lade S, Carney D, Tran H, et al. Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors. Br J Haematol. 2017;177:324\u20138.","journal-title":"Br J Haematol"},{"key":"2095_CR48","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.2020008276","volume":"138","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty S, Martines C, Porro F, Fortunati I, Bonato A, Dimishkovska M, et al. B-cell receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter transformation. Blood 2021;138:1053\u201366.","journal-title":"Blood"},{"key":"2095_CR49","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood.2022016272","volume":"140","author":"C Martines","year":"2022","unstructured":"Martines C, Chakraborty S, Vujovikj M, Gobessi S, Vaisitti T, Deaglio S, et al. Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo. Blood 2022;140:2335\u201347.","journal-title":"Blood"},{"key":"2095_CR50","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15746","volume":"8","author":"C Minici","year":"2017","unstructured":"Minici C, Gounari M, \u00dcbelhart R, Scarf\u00f2 L, D\u00fchren-von Minden M, Schneider D, et al. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat Commun. 2017;8:15746.","journal-title":"Nat Commun"},{"key":"2095_CR51","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature22353","volume":"546","author":"G Varano","year":"2017","unstructured":"Varano G, Raffel S, Sormani M, Zanardi F, Lonardi S, Zasada C, et al. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3\u03b2 inhibition. Nature 2017;546:302\u20136.","journal-title":"Nature"},{"key":"2095_CR52","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","volume":"11","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019;11:eaau1167.","journal-title":"Sci Transl Med"},{"key":"2095_CR53","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021;12:2877.","journal-title":"Nat Commun"},{"key":"2095_CR54","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/1878-0261.13115","volume":"16","author":"G Donati","year":"2022","unstructured":"Donati G, Rav\u00e0 M, Filipuzzi M, Nicoli P, Cassina L, Verrecchia A, et al. Targeting mitochondrial respiration and the BCL2 family in high\u2010grade MYC\u2010associated B\u2010cell lymphoma. Mol Oncol. 2022;16:1132\u201352.","journal-title":"Mol Oncol"},{"key":"2095_CR55","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.3390\/ijms21176014","volume":"21","author":"L Frattaruolo","year":"2020","unstructured":"Frattaruolo L, Brindisi M, Curcio R, Marra F, Dolce V, Cappello AR. Targeting the mitochondrial metabolic network: A promising strategy in cancer treatment. Int J Mol Sci. 2020;21:6014.","journal-title":"Int J Mol Sci"},{"key":"2095_CR56","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30396-3","volume":"13","author":"N Baran","year":"2022","unstructured":"Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, et al. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun. 2022;13:2801.","journal-title":"Nat Commun"},{"key":"2095_CR57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115\u201326.","journal-title":"Nat Med"},{"key":"2095_CR58","doi-asserted-by":"crossref","first-page":"24980","DOI":"10.18632\/oncotarget.25166","volume":"9","author":"HV Vangapandu","year":"2018","unstructured":"Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, et al. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget 2018;9:24980\u201391.","journal-title":"Oncotarget"},{"key":"2095_CR59","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/cancers12092400","volume":"12","author":"F Liu","year":"2020","unstructured":"Liu F, Kalpage HA, Wang D, Edwards H, H\u00fcttemann M, Ma J. et al.Cotargeting of Mitochondrial Complex I and Bcl-2 shows antileukemic activity against acute myeloid leukemia cells reliant on oxidative phosphorylation.Cancers. 2020;12:2400","journal-title":"Cancers"},{"key":"2095_CR60","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2022007034","volume":"6","author":"JAC van Bruggen","year":"2022","unstructured":"van Bruggen JAC, van der Windt GJW, Hoogendoorn M, Dubois J, Kater AP, Peters FS. Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells. Blood Adv. 2022;6:4185\u201395.","journal-title":"Blood Adv"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02095-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02095-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02095-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:03:31Z","timestamp":1709928211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02095-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2095"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02095-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"13 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.C. has been a consultant for Takeda, NanoString, AbbVie and Illumina; has received honoraria from Janssen, EUSPharma and Roche for speaking at educational activities and research funding from AstraZeneca and is an inventor on 2 patents filed by the National Institutes of Health, National Cancer Institute: \u201cMethods for selecting and treating lymphoma types,\u201d licensed to NanoString Technologies, and \u201cEvaluation of mantle cell lymphoma and methods related thereof\u201d, not related to this project. F.N. has received honoraria from Janssen, AbbVie, AstraZeneca\u00a0and Sophia Genetics\u00a0 for speaking at educational activities. D.C. has received honoraria from AbbVie, Sophia Genetics, Thermofisher\u00a0 and AstraZeneca for speaking at educational activities. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}